Project 3 comprises a collaborative effort between Research Triangle Institute (RTI) and Mycosynthetix, Inc.[MSX), both located in the Research Triangle Park area of North Carolina. The latter provides an under-explored source material (filamentous fungi;
specific aim 1) that serves to complement the collection ofDlants and culturing of cyanobacteria described in Project 2. Fungi will be selected from the MSX collectionn a manner that insures maximum chemical diversity, and this will involve a combination of geographic,ecological, and taxonomic information, as well as information on a strains ability to produce secondarymetabolites. Fungi will be cultured using complex media shown previously to support secondarymetabolism. MSX will scale-up the cultures of promising leads, providing a nearly limitless supply of desiredcompounds. RTI will carry out natural product isolation and structure elucidation studies (specific aim 2),and these will be monitored using the full breadth of biological resources available to the entire program,including in-house assays at RTI for restoration of EZH2 trimethylation activity toward lysine 27 of histone H3(H3-K27) and/or selective activity towards tumorigenic over non-tumorigenic breast adenocarcinoma cells(specific aim 3) as well as those biological targets described in Project 1, Core A, and Core C.EZH2 expression has been linked recently in a direct and causal fashion to transformation and metastasis ofhuman prostate, breast, and renal cell carcinoma, with inhibition of its H3-K27 trimethylation activityregulated ultimately by cell survival signals in vitro and in human tumor xenografts. Testing of extracts forcompounds that restore cellular EZH2 H3-K27 trimethylation activity should reveal mechanism-basedantitumor drug leads.Project 3 will interact with Project 1 for assistance with dereplication of samples via LC-MS and forpharmacological evaluation of their plant-based leads. It will interact with Project 2 for prioritization ofsamples via literature databases (NAPRALERT), and structure elucidation studies will be facilitated viacollaboration with the micro-coil NMR. Also, the samples will be tested in biological assays available to theentire team, as illustrated in Figure 3 of the Introduction. In doing so, the ultimate goal is to derive the mostpharmacological value from the chemistry and mycology efforts for the benefit of the entire Program. In thisA1 application, we have also re-designed our data management plans, and the entire Program will use arelational, real time database to coordinate, to exchange, to store, and to help prioritize the data (see CoreD).In total, Project 3 brings diverse source materials, proven chemistry, and innovative and complementarybiological targets, all for the use of the entire Program. Minor changes have been instituted since the initialapplication, and most of these constitute additions to the preliminary data (section C).
Showing the most recent 10 out of 144 publications
